



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corp. Office & Correspondence Address:

H-1, Zamrudpur Community Centre, Kailash Colony, New Delhi- 110 048

Tel: 011 29241099, 40587083, E-mail: mescogroup@rediffmail.com

13th February, 2016

Department of Corporate Services

BSE Ltd
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Ref: Symbol: MESCO PHARMACEUTICALS LTD, Scrip Code: 500274

Sub: Unaudited Financial Results for the Quarter ended 31st December, 2015

Dear Sirs

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial results for the quarter ended 31st December, 2015 along with Limited Review Report by Statutory Auditors.

We hope you will find the above in order.

Thanking you

Yours Faithfully
For Mesco Pharmaceuticals Ltd

For Mesco Pharmaceuticals Ltd.

N.S. Parameswaran
Managing Director Director
DIN: 00091097

Encl: a/a

N. Dhawan & Co

CHARTERED ACCOUNTANTS

411, Bhera Enclave, Paschim Vihar, Outer Ring Road, Delhi - 110 087

Call: 011-4234 2154, 93 135 10400, email: mail@ndhco.com


Review Report to MESCO PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the period ended December 31, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. Dhawan & Co.
Chartered Accountants
Firm Registration No. 007095N


Naresh Dhawan
Proprietor
M. No. 85968



Date: 13.02.2016
Place: New Delhi

MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895
 REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND
 Tel. : 011-29241099, E-mail : mescogroup@rediffmail.com


STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2015

SI No	PARTICULARS	Quarter Ended				Nine Month Ended		Year Ended	
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015	31.12.2014	31.03.2015
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED
1	Income from Operations (a) Net Sales/ Income from operations (Net of excise duty)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (net)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2	Expenses (a) Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Change in Inventories of finished goods and work in progress	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Employees Benefits Expenses	21344.00	0.00	0.00	21344.00	0.00	0.00	0.00	0.00
	(d) Depreciation and Amortisation expenses	0.00	0.00	117737159.00	0.00	353211477.00	465587604.42	3012.00	465587604.42
	(e) Other Expenses	625.00	625.00	3025.00	0.00	4275.00	0.00	0.00	0.00
	Total Expenses	21969.00	625.00	117740184.00	33519.00	353215752.00	465590616.42	3012.00	465590616.42
		(21,969.00)	(625.00)	(117,740,184.00)	(33,519.00)	(353,215,752.00)	(465,590,616.42)	0.00	(465,590,616.42)
3	Profit/(Loss) from Operations before other Income, Finance Costs & Exceptional Items (1-2)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4	Other Income	(21,969.00)	(625.00)	(117,740,184.00)	(33,519.00)	(353,215,752.00)	(465,590,616.42)	0.00	(465,590,616.42)
5	Profit/(Loss) from Ordinary Activities before finance costs and Exceptional Items (3+4)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6	Finance Costs	(21,969.00)	(808.00)	(117,740,184.00)	(33,702.00)	(355,268,590.00)	(467,643,636.42)	0.00	(467,643,636.42)
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit/(Loss) from Ordinary Activities before Tax (7-8)	(21,969.00)	(808.00)	(117,740,184.00)	(33,702.00)	(355,268,590.00)	(467,643,636.42)	0.00	(467,643,636.42)
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit/(Loss) from Ordinary Activities after Tax (9-10)	(21,969.00)	(808.00)	(117,740,184.00)	(33,702.00)	(355,268,590.00)	(467,643,636.42)	0.00	(467,643,636.42)
12	Extraordinary Items (net of tax expense)	(21,969.00)	0.00	(117,740,184.00)	(33,702.00)	(355,268,590.00)	(467,643,636.42)	0.00	(467,643,636.42)
13	Net Profit/(Loss) for the period (11-12)	(21,969.00)	0.00	(117,740,184.00)	(33,702.00)	(355,268,590.00)	(467,643,636.42)	0.00	(467,643,636.42)
14	Paid up Equity Share Capital (Face value Rs.10/- per Equity Share)	197381000.00	197381000.00	197381000.00	197381000.00	197381000.00	197381000.00	197381000.00	197381000.00
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	(299,176,994.00)	(299,176,994.00)	(299,176,994.00)	(299,176,994.00)	(299,176,994.00)	(299,176,994.00)	(299,176,994.00)	(299,176,994.00)
16	Earning per share (before and after extraordinary items) (Rs.10- each)	0.00	(0.00)	(5.79)	(0.00)	(17.48)	(22.70)	(22.70)	(22.70)
	Basic (Rs.)	(0.00)	(0.00)	(5.79)	(0.00)	(17.48)	(22.70)	(22.70)	(22.70)
	Diluted (Rs.)	(0.00)	(0.00)	(5.79)	(0.00)	(17.48)	(22.70)	(22.70)	(22.70)

Notes : The above Results, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on 13th February, 2016.

- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/re-arranged wherever necessary
- The above is an extract of the detailed format of Quarterly/ Nine months financial results filed with the Stock Exchange under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Mesco Pharma on behalf of the Board.


 N.S. PARAMESWARAN
 MANAGING DIRECTOR
 DIN : 00091097
 Director

PLACE NEW DELHI
 DATED : 13.02.2016